Price T Rowe Associates Inc Syndax Pharmaceuticals Inc Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 57,019 shares of SNDX stock, worth $714,448. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,019
Previous 48,927
16.54%
Holding current value
$714,448
Previous $942,000
19.96%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SNDX
# of Institutions
233Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$107 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$99.1 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$74.6 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$66.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$61.2 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $709M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...